Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84397 | 0.87 | LRRK2 (0.43) | SYKCDK4CCND1CDK6LRRK2 | |
| SCHEMBL10224744 | 0.86 | SYK (0.46) | SYKCDK4CCND1CDK6LRRK2 | |
| SCHEMBL13113410 | 0.76 | NR3C2 (0.44) | SYKLRRK2NR3C2SMOWNT3A | |
| SCHEMBL26141098 | 0.75 | ACACB (0.46) | CDK4CCND1CDK6LRRK2NR3C2 | |
| SCHEMBL14349214 | 0.74 | NR3C2 (0.44) | SYKCDK4CCND1CDK6LRRK2 | |
| SCHEMBL15185759 | 0.73 | LRRK2 (0.45) | SYKLRRK2SMO | |
| SCHEMBL14376036 | 0.71 | NR3C2 (0.47) | SYKLRRK2NR3C2WNT3A | |
| SCHEMBL21588286 | 0.69 | AKR1C3 (0.46) | SYKLRRK2NR3C2WNT3A | |
| SCHEMBL12235349 | 0.69 | NR3C2 (0.45) | SYKLRRK2NR3C2 | |
| SCHEMBL21588456 | 0.69 | AKR1C3 (0.46) | SYKLRRK2NR3C2WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | SYK 1136/4885CDK4 12/4885CCND1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.